3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
110
Specimen Handling
79
Magnetic Resonance Spectroscopy
70
Carboplatin
67
Cisplatin
66
Biopsy
57
Nivolumab
56
Radiotherapy
50
Cyclophosphamide
50
Paclitaxel
48
durvalumab
38
Radiation
37
Gemcitabine
37
olaparib
32
Rituximab
32
Etoposide
32
Dexamethasone
32
Doxorubicin
30
Docetaxel
30
atezolizumab
28
Lenalidomide
27
Ipilimumab
27
Taxes
26
Pemetrexed
25
Bevacizumab
25
Vincristine
24
Cytarabine
24
Prednisone
23
Platinum
23
Radiotherapy, Intensity-Modulated
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
trifluridine tipiracil drug combination
×
90 days
×
Clear all
NCT05064059
2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3
Completed
441 enrolled
24 charts